DDInter864 DDInter1676
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Histrelin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Histrelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risperidone
Histrelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Histrelin {u} may lead to a major life threatening interaction when taken with {v} Arsenic trioxide
Histrelin {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Histrelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Histrelin may lead to a major life threatening interaction when taken with Arsenic trioxide
Histrelin may lead to a major life threatening interaction when taken with Lefamulin